🇺🇸 FDA
Pipeline program

UB-221

UBP-A124-IgE

Phase 1 mab active

Quick answer

UB-221 for Chronic Spontaneous Urticaria is a Phase 1 program (mab) at China SXT Pharmaceuticals with 1 ClinicalTrials.gov record(s).

Program details

Company
China SXT Pharmaceuticals
Indication
Chronic Spontaneous Urticaria
Phase
Phase 1
Modality
mab
Status
active

Clinical trials